{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:18Z","timestamp":1787008398005,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":419,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1093\/annonc\/mdy256","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T23:40:40Z","timestamp":1532648440000},"page":"1932-1938","source":"Crossref","is-referenced-by-count":65,"title":["Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study"],"prefix":"10.1016","volume":"29","author":[{"given":"S.","family":"de Vos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Enschede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Petrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Verdugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kozloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1093\/annonc\/mdy256_bb0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"issue":"3","key":"10.1093\/annonc\/mdy256_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tibs.2013.12.006","article-title":"Many players in BCL-2 family affairs","volume":"39","author":"Moldoveanu","year":"2014","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"10.1093\/annonc\/mdy256_bb0020","doi-asserted-by":"crossref","first-page":"a008714","DOI":"10.1101\/cshperspect.a008714","article-title":"Mechanisms of action of Bcl-2 family proteins","volume":"5","author":"Shamas-Din","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"25","key":"10.1093\/annonc\/mdy256_bb0025","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy256_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2013.01.018","article-title":"ABT-199: taking dead aim at BCL-2","volume":"23","author":"Davids","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1093\/annonc\/mdy256_bb0035","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"10.1093\/annonc\/mdy256_bb0040","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2-family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1093\/annonc\/mdy256_bb0045","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1093\/annonc\/mdy256_bb0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12185-015-1911-0","article-title":"High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy","volume":"103","author":"Choi","year":"2016","journal-title":"Int J Hematol"},{"issue":"28","key":"10.1093\/annonc\/mdy256_bb0055","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy256_bb0060","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy256_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1093\/annonc\/mdy256_bb0070","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1093\/annonc\/mdy256_bb0075","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdy256_bb0080","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy256_bb0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Vacirca","year":"2014","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1093\/annonc\/mdy256_bb0090","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1093\/annonc\/mdy256_bb0095","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdy256_bb0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdy256_bb0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.617.617","article-title":"Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed\/refractory follicular lymphoma: interim data","volume":"128","author":"Zinzani","year":"2016","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/9\/1932\/25845234\/mdy256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:52:10Z","timestamp":1624683130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419341754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0923753419341754"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy256","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}